aTYR PHARMA (ATYR) Current Assets (2014 - 2026)
aTYR PHARMA's (ATYR) quarterly Current Assets came in at $67.6 million in Q1 2026, down 18.85% YoY from $83.3 million in Q1 2025, and down 15.78% on a QoQ basis from $80.2 million in Q4 2025.
aTYR PHARMA (ATYR) Current Assets (2014 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has 13 years of Current Assets data on file, last reported at $67.6 million in Q1 2026.
- Quarterly Current Assets fell 18.85% year-over-year to $67.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $67.6 million (down 18.85% YoY) and the FY2025 annual result came in at $80.2 million, down 2.1% from the prior year.
- Current Assets eased to $67.6 million in Q1 2026, from $80.2 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $119.4 million in Q1 2023 to a low of $67.6 million in Q1 2026.
- A 5-year average of $92.0 million and a median of $90.3 million in 2024 frame the typical range for Current Assets.
- The widest YoY moves for Current Assets: up 101.17% in 2022, down 30.38% in 2022.
- Tracing ATYR's Current Assets over 5 years: stood at $80.9 million in 2022, then advanced by 27.35% to $103.0 million in 2023, then fell by 20.43% to $82.0 million in 2024, then slipped by 2.1% to $80.2 million in 2025, then declined by 15.78% to $67.6 million in 2026.
- The last three Current Assets figures came in at $67.6 million (Q1 2026), $80.2 million (Q4 2025), and $93.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | aTYR PHARMA | 49.54 Mn | -7.87 Mn | - | 58.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 58.36 Mn |
| Mar 31, 2026 | 67.58 Mn |
| Dec 31, 2025 | 80.24 Mn |
| Sep 30, 2025 | 93.01 Mn |
| Jun 30, 2025 | 87.49 Mn |
| Mar 31, 2025 | 83.27 Mn |
| Dec 31, 2024 | 81.95 Mn |
| Sep 30, 2024 | 76.32 Mn |
| Jun 30, 2024 | 90.30 Mn |
| Mar 31, 2024 | 96.92 Mn |
| Dec 31, 2023 | 102.99 Mn |
| Sep 30, 2023 | 107.30 Mn |
| Jun 30, 2023 | 114.43 Mn |
| Mar 31, 2023 | 119.45 Mn |
| Dec 31, 2022 | 80.87 Mn |
| Sep 30, 2022 | 84.63 Mn |
| Jun 30, 2022 | 93.36 Mn |
| Mar 31, 2022 | 103.12 Mn |
| Dec 31, 2021 | 113.57 Mn |
| Sep 30, 2021 | 121.57 Mn |